Company research / XGN

Exagen Inc. (XGN)

SEC name EXAGEN INC. · CIK 0001274737 · Nasdaq · Services-Medical Laboratories

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Exagen Inc. reported revenue of $66.58M. Revenue grew 19.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $71.12M.

Key ratios (year ended 2025-12-31)

58.3%
Gross margin
-21.1%
Operating margin
-30.0%
Net margin
-114.3%
Return on year-end equity
19.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-20

Headquarters locality: Vista · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$71.12M$66.58M$55.64M$52.55M$45.56M$48.30M$41.98M$40.39M$32.44M
Cost of Revenue$29.42M$27.78M$22.53M$23.09M$24.21M$20.59M$16.56M$18.81M$15.38M
Gross Profit$41.70M$38.80M$33.11M$29.46M$21.35M$27.71M$25.42M$21.58M$17.06M
R&D Expense$6.47M$6.25M$5.38M$4.87M$9.88M$7.24M$3.57M$2.18M$2.12M
Operating Income-$13.21M-$14.07M-$13.64M-$22.84M-$46.05M-$24.07M-$15.19M-$9.30M-$4.88M
Depreciation & Amortization$2.40M$2.10M$1.70M$2.20M$1.60M$900.0K$500.0K$600.0K$600.0K
EBITDA-$10.81M-$11.97M-$11.94M-$20.64M-$44.45M-$23.17M-$14.69M-$8.70M-$4.28M
Net Income-$18.92M-$19.95M-$15.12M-$23.69M-$47.39M-$26.85M-$16.69M-$12.04M-$8.01M
EPS (Diluted)n/a-$0.93-$0.83-$1.34-$2.77-$1.68-$1.32n/an/a
Total Assets$51.94M$58.02M$44.69M$56.94M$86.22M$123.44M$78.38M$88.31M$28.89M
Total Liabilities$39.72M$40.57M$35.15M$34.25M$43.76M$38.51M$36.54M$32.65M$35.62M
Long-Term Debt$22.84M$22.91M$20.25M$19.50M$28.97M$27.48M$26.66M$25.85Mn/a
Shareholders' Equity$12.22M$17.45M$9.54M$22.69M$42.46M$84.94M$41.84M$55.66M-$111.97M
Cash & Equivalents$24.59M$32.22M$22.04M$36.49M$62.39M$99.44M$57.45M$72.08M$13.16M
Operating Cash Flow-$6.50M-$13.62M-$13.28M-$14.46M-$32.14M-$20.27M-$14.08M-$9.71M-$9.30M
Capital Expenditures$1.09M$641.0K$515.0K$828.0K$4.32M$2.37M$455.0K$403.0K$199.0K
Free Cash Flow-$7.59M-$14.27M-$13.79M-$15.29M-$36.46M-$22.64M-$14.54M-$10.11M-$9.50M
Shares Outstanding24.19M22.91M17.64M17.05M16.55M16.16M12.65M12.56M63.0K
Weighted Average Diluted Sharesn/a21.56M18.20M17.68M17.08M15.97M12.63Mn/an/a
EPS (Basic)n/a-$0.93-$0.83-$1.34-$2.77-$1.68-$1.32n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView